MMJ Recs

MAY 9, 2024

In this instance, medical cannabis offers a promising alternative or complementary treatment option. Navigating the complexities surrounding the Veterans Administration and medical cannabis can be daunting. Many veterans struggle with various physical and psychological conditions resulting from their service.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JULY 28, 2021

Reporting to the Regulatory Affairs Manager, the RPS supports functions related to tracking regulatory information and document styling and publishing in eCTD format for regulatory submissions. Position duties: Electronic document preparation and submission of electronic common technical document (eCTD) submissions to regulatory agencies.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

JUNE 19, 2022

The market for psychedelic substances is projected to grow rapidly, potentially outpacing the legal US cannabis market. For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art.

Clinical Trials 52

Clinical Trials Microdosing Data Pharmaceutical 52

Cannabis Law Report

FEBRUARY 5, 2022

Responsible for creation and maintenance of all regulatory documentation, including but not limited to, product packaging, labelling, inserts, working in conjunction with the marketing team for design, and assuring regulatory compliance across all territories. Support new product development and further clinical activities.

Medicine 52

Medicine Research and Development Clinical Trials Pharmaceutical 52

Cannabis Law Report

DECEMBER 15, 2021

Responsible for creation and maintenance of all regulatory documentation, including but not limited to, product packaging, labelling, inserts, working in conjunction with the marketing team for design, and assuring regulatory compliance across all territories. Support new product development and further clinical activities. 2 days ago.

Medicine 52

Medicine Research and Development Clinical Trials Pharmaceutical 52

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Ensure high quality, timely, and consistent submission of regulatory documents. European Regulatory Lead Executive Summary. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

NOVEMBER 7, 2021

WA Upper House MP Brian Walker is in the spotlight over potential conflict of interests concerns after he was appointed ‘strategic consultant’ to an ASX-listed medicinal cannabis company. Legalise Cannabis WA MP Brian Walker denies conflict over medicinal cannabis company. Cannabiz reported Friday.

Medicine 52

Medicine Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Ensure high quality, timely, and consistent submission of regulatory documents. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Canna Care Docs

JUNE 18, 2018

For those who might be exploring the benefits of cannabis or are considering its many therapeutic effects, Cannabidiol, often abbreviated as CBD is especially important for cannabis patients. CBD possess a wide array of therapeutic effects, without the psychoactive and intoxicating effects that are typically associated with cannabis.

Clinical Trials 75

Clinical Trials CBD Epilepsy Patients 75

Veriheal

MAY 3, 2022

Cannabis use disorder (CUD) is often confused with frequent cannabis use , but CUD is significantly more worrisome. The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Veriheal

JULY 16, 2020

Despite the novelty of its drug policy findings, the document has gone largely unnoticed by reform advocates and the media. The panel, led by Jake Leinenkugel (a presidential nominee), asserted that psychedelics, such as MDMA and psilocybin, as well as cannabis, present promising ways to treat mental health conditions among military veterans.

Research and Development 95

Research and Development Clinical Trials Treatment Compliance 95

Cannabis Law Report

MARCH 1, 2022

Manage the writing and/or review of key documents for INDs, IMPDs and CTAs and other regulatory submissions, as required. Contribute to the production of project-related documents, budgets, presentations, patents and regulatory submissions as required. . +5 Represent the company as the Regulatory Affairs expert before U.S.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

JULY 30, 2019

Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any proof of safety or effectiveness. This unprecedented proposal is contained in the government’s consultation document on giving greater access to medicinal cannabis.

Medicine 40

Medicine Clinical Trials Safety Access 40

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. The Wrong Type of Cannabis. . Drug Enforcement Administration is not a fan of drugs or legalization.

DEA 111

DEA Research and Development Clinical Trials Cannabis 111

Cannabis Law Report

OCTOBER 2, 2021

Manage the writing and/or review of key documents for INDs, IMPDs and CTAs and other regulatory submissions, as required. Contribute to the production of project-related documents, budgets, presentations, patents and regulatory submissions as required. . +5 Represent the company as the Regulatory Affairs expert before U.S.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

FEBRUARY 10, 2022

Despite Petitioners’ noble cause, the case turned on a technicality after the Court determined that the DEA’s letter stating that such psilocybin treatment was not allowed, the document that prompted the lawsuit, was not a “final” decision of the Attorney General that the Court had jurisdiction to review. Background. Psilocybin. The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

FEBRUARY 2, 2022

– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA). This application comes on the heels of Colombia’s new legislation requiring insurance companies to cover cannabis prescriptions. “I About Flora Growth Corp.

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. People want to trust their doctors, but doctors need knowledge. We have a ways to go,” Tan said.

Education 101

Education Clinical Trials Medicine Policy 101

Cannabis Law Report

AUGUST 25, 2021

Acquisition Advances Company’s Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis. Kotra taking on the role of leading the development of FSD Pharma’s drug development pipeline in Psychedelics and Medical Cannabis. Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Puff Puff Post

OCTOBER 3, 2019

Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum. The cannabis compound referred to as cannabidivarin (CBDV) is a non-psychoactive chemical that does not cause a “high” when consumed.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . For cannabis, the ongoing restriction as a Schedule I substance will eventually come to an end. Some states in the U.S.

DEA 52

DEA Research and Development Clinical Trials Extraction 52

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. The program imposes strict limitations on the THC content in the prescribed cannabis, ensuring that it remains at a very low level.

Law 52

Law Dispensary Clinical Trials Programs 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. Types of Research.

Research and Development 108

Research and Development Data THC Clinical Trials 108

CannaMD

OCTOBER 29, 2020

But, while contraband cannabis might not be a concern, the very real threat that candy poses to the American population is alarming. So this Halloween, we invite you to join us as CannaMD takes a brave look at five times candy – in all its high-glycemic glory –was way scarier than cannabis. Cannabis: 1. Cannabis: 2.

Research and Development 92

Research and Development Blood Pressure Data Clinical Trials 92

Veriheal

NOVEMBER 17, 2020

Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. Ohio became the 25th state to legalize medical cannabis back on June 8 of 2016. Medical cannabis is now available to residents in Ohio who meet one of 22 qualifying conditions laid out by House Bill 523.

Conditions 98

Conditions Research and Development Pharmaceutical Clinical Trials 98

Cannabis Law Report

JANUARY 6, 2022

Tim Leslie brings significant experience in both the cannabis industry and international growth and business development, including an extensive career at Amazon, to the organization. Since his time there, Leslie has served on the board of renowned cannabis companies before his appointment as Chairman of the Board of Advisors at Flora. “I

Research and Development 52

Research and Development Events Clinical Trials Business 52

CannaMD

MAY 25, 2021

These findings could point to new cannabis-based therapies for both the healing of broken bones and the slowing of degenerative osteoporosis. A recent study documented bone healing in rodents with broken femoral bones, in which subjects were injected with a formula of either THC or CBD. THC, CBD & THE ECS.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

MedicalJane

JUNE 29, 2018

None of the approved drugs contain, or are derived from, the whole cannabis plant. a Canada-based medical cannabis firm. “It rapidly destigmatizes what cannabis can do.” Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

AUGUST 23, 2021

At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. Since the year-end, the £2.6

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Project CBD

AUGUST 6, 2019

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. cannabis sector, real estate, and a consumer-targeted biotechnology venture. Cannabis-related Practices or Activities are Illegal Under U.S. Learn more at www.immunoflex.com. federal law. federal law.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

JUNE 9, 2022

Ukraine’s Health Minister Viktor Liashko announced on June 7 that the government had backed the bill that would legalize medical cannabis amid the war with Russia. The bill aims to improve the quality of medical services for the population that undergoes palliative medicine and encourage medical research on cannabis.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Project CBD

AUGUST 6, 2019

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

Puff Puff Post

OCTOBER 3, 2019

Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum. The cannabis compound referred to as cannabidivarin (CBDV) is a non-psychoactive chemical that does not cause a “high” when consumed.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

MMJ Recs

APRIL 10, 2021

The vaccine was designed to protect people from the coronavirus and went through extensive clinical trials to test its safety. Does cannabis affect vaccination effectiveness? If you’re worried about cannabis and COVID-19, your best bet is to use edibles or tinctures when imbibing. Call your doctor.

Clinical Trials 52

Clinical Trials Safety Patients Tincture 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC is a Public Benefit Corporation, with a dual mandate to generate shareholder value and public benefit.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40